- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00975325
Bioequivalence Study Comparing Two Test Products With One Reference Product, All Containing 5 mg Yohimbine
Characterisation of Relative Bioavailability and Assessment of Bioequivalence of Two Generic Yohimbine Formulations in Comparison With a Marketed Reference Product - an Open, Randomised, Single Dose, 3-period Change-over Study
- Type: Bioequivalence study in male healthy volunteers, therapeutical indication (erectile disfunction) not studied
Products, dosage, and route of administration:
- Test 1: Yohimbin "Spiegel"® (Desma GmbH, Germany), tablet containing 5 mg yohimbine hydrochloride, oral administration
- Reference: Yocon-Glenwood® (Glenwood GmbH, Germany), tablet containing 5 mg yohimbine hydrochloride, oral administration
Duration of treatment:
2 single-dose administrations of 5 mg yohimbine hydrochloride each under fasting conditions separated by a wash-out period of at least one week i.e. 6 treatment free days between all administrations
Study Overview
Detailed Description
Study objectives
Primary Objectives:
- Characterisation of relative bioavailability of Test 1 in comparison to Reference after single dose administration under fasting conditions
- Assessment of bioequivalence of Test 1 vs. Reference after single dose administration under fasting conditions, determined by use of area under the concentration time curve AUC0-tlast and maximal concentration Cmax obtained for yohimbine
Secondary Objective:
- Descriptive characterisation of safety and tolerability of the investigational products in the study population
- Descriptive characterisation of blood pressure and pulse rate around Cmax of the investigational products in the study population
Analytical methodology:
Yohimbine in plasma samples will be analysed by use of a validated HPLC-MS/MS; intended LLOQ for yohimbine is 0.5 ng/ml
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Erfurt, Germany, D-99084
- SocraTec R&D GmbH
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Sex: male
- Ethnic origin: Caucasian
- Age: 18 - 55 years, inclusive
- Body-mass index1 (BMI): ≥ 19 kg/m² and ≤ 27 kg/m²
- Good state of health
- Non-smoker or an ex-smoker for a least 1 month
- Written informed consent, after having been informed about benefits and potential risks of the trial, as well as details of the insurance taken out to cover the subjects participating in the study
Exclusion Criteria:
Safety concerns:
- Existing cardiac or haematological diseases and/or pathological findings, which might interfere with the safety, tolerability, absorption and/or pharmacokinetics of the active ingredient
- Existing hepatic and/or renal diseases and/or pathological findings, which might interfere with the safety, tolerability, absorption and/or pharmacokinetics of the active ingredient
- Existing gastrointestinal diseases and/or pathological findings, which might interfere with the safety, tolerability, absorption and/or pharmacokinetics of the active ingredient
- History of relevant CNS and/or psychiatric disorders and/or currently treated CNS and/or psychiatric disorders
- Pathological ECG (12 standard leads) which might interfere with the safety of the active ingredient
- Known allergic reactions to the active ingredients used or to constituents of the pharmaceutical preparations
- Subjects with severe allergies or multiple drug allergies
- Systolic blood pressure <100/>140 mmHg
- Diastolic blood pressure <60/>90 mmHg
- Pulse rate <45/>110 bpm
- Laboratory values out of normal range unless the deviation from normal is judged as not relevant for the study by the investigator
- Positive anti-HIV-test, HBs-AG-test or anti-HCV-test
- History of glaucoma
- Lack of suitability for the trial 14. Subjects exhibiting extreme genetic polymorphism of CYP 2D6 - "Poor or Ultra-rapid metabolizer" 15. Acute or chronic diseases which could affect absorption or metabolism 16. History of or current drug or alcohol dependence 17. Regular intake of alcoholic food or beverages of ≥ 40 g pure ethanol for male per day 18. Subjects who are on a diet which could affect the pharmacokinetics of the active ingredient 19. Regular intake of caffeine containing food or beverages of ≥ 500 mg per day 20. Blood donation or other blood loss of more than 400 ml within the last two months prior to individual enrolment of the subject 21. Participation in a clinical trial during the last two months prior to individual enrolment of the subject 22. Regular treatment with any systemically available medication (except continuous usual replacement therapy e.g. L-thyroxine) within two weeks prior to the first administration of the study medication 23. Intake of yohimbine for any reason (e.g. fat burning, weight reduction, muscle improvement, post operative care and/or any therapy for erectile dysfunctions) within two weeks prior to first administration of the study medication 24. Subjects, who report a frequent occurrence of migraine attacks
- Administrative reasons 25. Subjects suspected or known not to follow instructions 26. Subjects who are unable to understand the written and verbal instructions, in particular regarding the risks and inconveniences they will be exposed to during their participation in the study
Study Plan
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Yohimbine, Yohimbine "Spiegel"
|
yohimbine 5 mg, one tablet, single dose only
|
Active Comparator: Yohimbine Yocon-Glenwood
|
yohimbine 5 mg, one tablet, single dose only
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Pharmacokinetic parameter AUC, Cmax
Time Frame: Day 1
|
Day 1
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Frank Donath, MD, SocraTec R&D GmbH
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Sexual Dysfunctions, Psychological
- Sexual Dysfunction, Physiological
- Erectile Dysfunction
- Physiological Effects of Drugs
- Adrenergic Antagonists
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Urological Agents
- Adrenergic alpha-Antagonists
- Mydriatics
- Adrenergic alpha-2 Receptor Antagonists
- Yohimbine
Other Study ID Numbers
- YOH-BE-2009
- EudraCT No.2009-013122-16
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Erectile Dysfunction
-
University of VirginiaActive, not recruitingErectile Dysfunction | Erectile Dysfunction Following Radical Prostatectomy | Erectile Dysfunction Following Radiation Therapy | Erectile Dysfunction Due to General Medical Condition | Erectile Dysfunction Due to Arterial InsufficiencyUnited States
-
Cairo UniversityRecruitingErectile Dysfunction | Erectile Dysfunction Following Radical Prostatectomy | Erectile Dysfunction Following Simple Prostatectomy | Erectile Dysfunction With Diabetes Mellitus | Erectile Dysfunction Due to Arterial Disease | Erectile Dysfunction Due to Injury | Erectile Dysfunction Due to Neuropathy and other conditionsEgypt
-
University of BaghdadCompletedSexual Dysfunction | Erectile Dysfunction | Erectile Dysfunction Following Radical Prostatectomy | Erectile Dysfunction Following Radiation Therapy | Sexual Abstinence | Erectile Dysfunction With Diabetes Mellitus | Sexual Desire Disorder | Erectile Dysfunction Following Cryotherapy | Erectile Dysfunction... and other conditionsIraq
-
BayerCompletedSexual Dysfunction | Male Erectile DysfunctionBelgium, Italy, France, Germany, Spain, Netherlands, South Africa
-
Cairo UniversityCompletedVasculogenic Erectile DysfunctionEgypt
-
InitiaTerminatedVasculogenic Erectile DysfunctionIsrael
-
InitiaCompletedVasculogenic Erectile DysfunctionIsrael
-
InitiaCompletedVasculogenic Erectile DysfunctionCzech Republic, Lithuania, Netherlands, Palestinian Territories, Occupied
-
Rexahn Pharmaceuticals, Inc.CompletedErectile Dysfunction (ED)United States
-
SK Chemicals Co., Ltd.TerminatedMale Erectile Dysfunction
Clinical Trials on Yohimbine
-
Nathaniel M. RobbinsWithdrawnParkinson DiseaseUnited States
-
Hospices Civils de LyonCompleted
-
Medical University of ViennaCompletedOcular Physiology | Autoregulation | Blood Flow VelocityAustria
-
Charite University, Berlin, GermanyCompletedPlacebo | Hydrocortisone | Yohimbine | Yohimbine + HydrocortisoneGermany
-
Charite University, Berlin, GermanyCompletedMajor Depressive Disorder | Early Life TraumaGermany
-
Mayo ClinicNational Institutes of Health (NIH)Completed
-
National Institute of Mental Health (NIMH)CompletedDepression, Involutional | Major DepresssionUnited States
-
Wayne State UniversityNot yet recruitingOpioid Use DisorderUnited States
-
Southern Methodist UniversityCompletedSocial Anxiety DisorderUnited States
-
University of North Carolina, Chapel HillNot yet recruitingBorderline Personality DisorderUnited States